Joining the study

Approximately **125 people** with hepatocellular carcinoma will join the **EMERALD-Y90 Study** in around 20 study centers across the **USA**.

The EMERALD-Y90 Study is recruiting individuals:

- Aged **at least 18 years**.
- Diagnosed with **hepatocellular carcinoma**.
- From all races and ethnicities.

The study team will explain the details of the study, including the procedures involved, potential risks and benefits, and address any questions you have before you decide whether to participate. Contacting us to find out more does not mean that you must join the study.



To learn more about the EMERALD-Y90 Study, please contact:

Study center: _____

Contact: _____

Telephone: _____

Email: _____

Website: _____

Thank you for your interest in the EMERALD-Y90 Study.

EMERALD-Y90
AZ IO TRIALS

D933GC00002
273131 USA Study Information Brochure 20230821 1.0 English

The EMERALD-Y90 Clinical Research Study

Participant information brochure

EMERALD-Y90
AZ IO TRIALS

About the study

EMERALD-Y90 is a **clinical research study** for people with a type of liver cancer known as **hepatocellular carcinoma**.

It is looking at the study drug combination of **durvalumab** and **bevacizumab** given after the **TARE Y90** procedure.

Although all three treatments are already approved for use in liver cancer, this approach is investigational, meaning that it has not been approved for use outside of a clinical study.

Durvalumab is a type of anticancer drug that helps your immune system to attack and kill cancer cells.

Bevacizumab is an anticancer drug that reduces blood flow to the tumor to starve the cancer of the nutrients it needs.

TARE (which stands for *transarterial radioembolization*) is a procedure that delivers tiny beads holding radioactive particles (known as *yttrium-90*) directly to liver tumors to kill cancer cells.

Participant journey and study treatments

Screening

You will complete health assessments and medical imaging scans to confirm you can join the study.

TARE procedure

This involves a thin tube being inserted into a blood vessel in the groin and then guided to the liver. You will be sedated during this procedure.

Durvalumab

You will be given **one dose of durvalumab** via a plastic tube into a vein (known as an *intravenous infusion*), 2 weeks after the TARE.

Durvalumab plus bevacizumab

After a further 2 weeks, you will begin **durvalumab plus bevacizumab** via intravenous infusions, which will be repeated **every 3 weeks**.

The study doctor will decide how many sessions of this study treatment you receive, depending on how you respond.

The study duration will be different for each participant but could be an average of around 2 years.

All study treatment and medical care will be provided at no cost. You can leave the study at any time, for any reason.

Monitoring your health throughout the study and beyond

The study team will check your health using medical tests and questionnaires every time you visit the study center for your study treatment.

When you finish the study treatment, there will be 4 follow-up study center visits every 30 days to continue these health checks.

After this, the study team will contact you by telephone every 12 weeks to check on your well-being.

Your health and well-being are our utmost priority.

EMERALD-Y90

AZ IO TRIALS